Accustem Sciences (Accustem Sciences) Common Stock : $0.01 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Common Stock?

Accustem Sciences's quarterly common stock stayed the same from Sep. 2023 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) and stayed the same from Dec. 2023 ($0.01 Mil) to Mar. 2024 ($0.01 Mil).

Accustem Sciences's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2022 ($0.01 Mil) but then stayed the same from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil).

Accustem Sciences Common Stock Historical Data

The historical data trend for Accustem Sciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Common Stock Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Common Stock

0.01

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial				0.01	0.01	0.01	0.01	0.01

Accustem Sciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Accustem Sciences (Accustem Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001

Website

http://www.accustem.com

Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.